Greenberg Traurig shareholders Drew Altman and David Wells in Miami. Courtesy photos
It may sound outlandish, but two Miami attorneys who specialize in corporate law can take some credit for the proliferation of cell and gene therapies.
Greenberg Traurig shareholders Drew Altman and David Wells advised on the $380 million acquisition of HemaCare Corp., a supplier of customized human biomaterials to cell and gene therapy researchers, to Charles River Laboratories Inc. The attorneys represented HemaCare closing the deal on Jan. 3.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
